Outcome of the Exercise of Warrants in NeuroVive

Lund, Sweden, 10 December 2018 –NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or “the Company”) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announces the outcome of the exercise of warrants of series 2018:1, issued in conjunction with the Company’s rights issue of units in April, 2018. The exercise period ended on 30 November 2018 and in total 126,235 warrants were exercised for the subscription of 126,235 shares at a subscription price of SEK 3.80 per share. Thus, NeuroVive will receive approximately TSEK 480 before issuance costs.

Exercised warrants have been replaced with interim shares pending registration by the Swedish Companies Registration Office (Sw. Bolagsverket). Conversion of interim shares to shares is expected to take place about 18 December 2018.

Number of Shares and Share Capital
Through the exercise of warrants, the number of shares in NeuroVive will increase by 126,235 shares, from 91,570,841 to 91,697,076 shares. The share capital will increase by SEK 6,311.75, from SEK 4,578,542.05 to SEK 4,584,853.80.

The information was submitted for publication, through the agency of the contact person set out below, at 08.30 a.m. CET on 10 December 2018.

For additional information, please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@neurovive.com, www.neurovive.com
For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/ 

About NeuroVive 
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).